Real-world study tracks guselkumab's impact on IBD patients
NCT ID NCT07102368
First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times
Summary
This study will follow 500 people with Crohn's disease or ulcerative colitis who are starting guselkumab, a biologic drug. Researchers will measure how many achieve remission and how the treatment affects daily life, including fatigue and work productivity. The goal is to understand how well the drug works outside of clinical trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- guselkumab
- What this could lead to
- If successful, this study could confirm that guselkumab is an effective treatment option for inflammatory bowel disease in real-world settings.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be influenced by other factors. It does not test a new drug, only gathers data on existing use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLITIS, ULCERATIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Praxis Fur Gastroenteroligie
RECRUITINGBerlin, 10825, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can pregnancy and neurological disease coexist safely? a new registry seeks answers
- Could IBD medications during pregnancy shape a Child's development?
- AI reads scans to forecast Crohn's complications
- Can stem cell vesicles heal Crohn's fistulas?
- Can AI learn to grade endoscopy quality from video?
- Can a new drug calm the Gut's overactive immune response in Crohn's?